Latest Healthtech Startup Funding Rounds
Companies building technology for healthcare delivery, diagnosis, clinical workflows and patient access.
- Rounds
- 744 Jan 1 – Oct 24, 2026
- Disclosed funding
- $25.3B 606 disclosed amounts
- Median round
- $16M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| x Transforms fragmented medical records into decision-ready data | $46M | Series B | Healthtech | United States | Investors | |
| AH Assort HealthCompany profile Provides AI-powered patient journey platform for healthcare organizations Provides AI-powered patient journey platform for healthcare organizations | $120M | Series CSeries C+ | Healthtech | United States | Investors | |
| OB Ollin BiosciencesCompany profile Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD | $330M | Series B | Healthtech, Biotech | United States | Investors | |
| AN Anodyne NanotechCompany profile Develops transdermal microneedle patches delivering GLP-1 and biologic therapeutics without injections Develops transdermal microneedle patches delivering GLP-1 and biologic therapeutics without injections | $12.6M | Series A | Healthtech, Biotech | United States | Investors | |
| RB RQ BioCompany profile Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients | $115M | Series A | Healthtech, Biotech | United Kingdom | Investors | |
| C CroíValveCompany profile Develops a transcatheter device to treat tricuspid regurgitation in patients with structural heart disease Develops a transcatheter device to treat tricuspid regurgitation in patients with structural heart disease | $27M | Series B | Healthtech | Ireland | Investors | |
| RH Rapalogix HealthCompany profile Develops prescription therapeutics and skincare products for cellular longevity and skin health Develops prescription therapeutics and skincare products for cellular longevity and skin health | $20M | Series A | Healthtech, Biotech | United States | Investors | |
| C Automates chronic care for older adults using AI | $100M | Series CSeries C+ | Healthtech | United States | Investors | |
| NB NorthLinks BioCompany profile Develops broad-spectrum antiviral prophylactic therapies for respiratory infections Develops broad-spectrum antiviral prophylactic therapies for respiratory infections | $34M | Undisclosed | Healthtech, Biotech | United States | Investors | |
| OB Osanni BioCompany profile Platform that discovers and de-risks novel drug programs in ophthalmology and cardiology via affiliate company model Platform that discovers and de-risks novel drug programs in ophthalmology and cardiology via affiliate company model | $190M | Series B | Healthtech, Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1General Catalyst
Baba, Disha (formerly Curelink), Thatch
23rounds2led - 2Y Combinator (YC)
Vitalize, Angle Health, Metriport
21rounds0led - 3Alumni Ventures
MintNeuro, Evvy, Hopscotch Primary Care
13rounds0led - 4Andreessen Horowitz (a16z)
Sharp Performance, General Medicine, Devoted Health
12rounds2led - 5Khosla Ventures
Even Healthcare, Abby Care, Rightway
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.